<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892577</url>
  </required_header>
  <id_info>
    <org_study_id>JS-1391</org_study_id>
    <nct_id>NCT03892577</nct_id>
  </id_info>
  <brief_title>Real-world Study for Patients With Advanced Hepatobiliary Tumors</brief_title>
  <official_title>Real-world Study for Targeted Therapy and Immunotherapy in Patients With Advanced Hepatobiliary Tumors: a Multi-centers, Open-assess Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OrigiMed., Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators design a large sample size study in the real-world to explore whether
      targeted therapy and immunotherapy can improve the survival, quality of life and drug safety
      of patients with advanced hepatobiliary tumors, and analyze the correlation between genetic
      variation and the effectiveness of therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a multicenter, non-random, open and observational real-world study. It is
      estimated that 2000 patients with advanced hepatobiliary tumors will be enrolled in about 20
      research centers. And it is planned to complete the enrollment within 2 years and it is
      expected that all enrolled subjects will reach the observation end point in 5 years.

      After primary screening of all the patients, the investigators will further collect
      next-generation sequence(NGS) data and immunohistochemical data from the subjects, and enroll
      patients with any type of the following three treatment program: 1. Monotherapy or
      combination therapy with the targeted drug related to genetic variation of the subject; 2.
      Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib,
      apatinib, etc; 3. Immunotherapy or immunotherapy combined with targeted therapy.

      The investigators will collect subjects' data from assessment centers each month and the
      efficacy, quality of life, and safety of treatment will be evaluated.

      This trial plans to conduct an interim analysis and final analysis after collecting 500
      cases, 1000 cases, and 2000 subjects, and explore the clinical application value of targeted
      therapy and immunotherapy in advanced hepatobiliary tumors in real world.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>one year</time_frame>
    <description>Percentage of subjects with complete response and partial response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>six months</time_frame>
    <description>A duration from the date of initial treatment with apatinib to disease progression (as defined by RECIST) or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>two years</time_frame>
    <description>Time from the date of initial treatment to death for any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>six months</time_frame>
    <description>Percentage of subjects with complete remission, partial remission, or stable disease during treatment or within 30 days of termination of test drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Event</measure>
    <time_frame>one year</time_frame>
    <description>Percentage of subjects who develop any adverse events (CTCAE 4.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL) after treatment</measure>
    <time_frame>one year</time_frame>
    <description>The life quality of every subject will be assessed every 3 months according to the 45-item FACT-Hep questionnaire, which assesses generic HRQL concerns and disease-specific issues.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Objective Response Rate</condition>
  <condition>Progression-free Survival</condition>
  <condition>Overall Survival</condition>
  <condition>Disease Control Rate</condition>
  <condition>Duration of Response</condition>
  <condition>Five-year Survival Rate</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Patients with advanced hepatobiliary tumors</arm_group_label>
    <description>2000 patients with advanced hepatobiliary tumors will be enrolled and the enroll patients should be treat with any type of the following three treatment program: 1. Monotherapy or combination therapy with the targeted drug related to genetic variation of the subject; 2. Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib, apatinib, etc; 3. Immunotherapy or immunotherapy combined with targeted therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Precision oncology including targeted therapy and immunotherapy</intervention_name>
    <description>Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.</description>
    <arm_group_label>Patients with advanced hepatobiliary tumors</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      High-Throughput Sequencing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients With Advanced Hepatobilary Tumors.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following criteria：

          1. ≥18 years old, gender is not limited, and life expectancy is at least 6 months.

          2. Diagnosed as primary liver cancer or biliary malignant tumor by histopathology or
             cytology.

          3. The Barcelona staging classification: class C.

          4. Child-Pugh classification: class A.

          5. At least one measurable lesion (RECIST v1.1)

          6. Unable to perform radical surgery or patient refuse surgery.

          7. Subjects fail to have first-line treatment and need palliative treatment, and have
             received or are undergoing any of the following three treatments:

               -  Monotherapy or combination therapy with targeted drug associated with genetic
                  variation in the subject.

               -  Or, treat with pan-target anti-vascular drugs, such as sorafenib, regorafenib,
                  lenvatinib, apatinib.

               -  Or, immunotherapy or immunotherapy combined with targeted therapy.

          8. Subjects volunteer to participate in the study and sign informed consent.

        Exclusion Criteria:

        Patients with one or more of the following criteria should be excluded:

          1. Patients with early hepatobiliary tumor.

          2. The Barcelona staging classification: class A or B.

          3. Child-Pugh classification: class B or C.

          4. Radical surgical resection.

          5. CT or MRI shows unclear tumor boundary or no measurable lesions (RECIST v1.1).

          6. Drug abuse, or any medical, psychological, or social condition that may affect the
             study, patient compliance, or even compromise the safety of the patient.

          7. Conduct other experimental drug treatments other than this test within 4 weeks before
             the start of the study; or participate in another clinical study that has an impact on
             the results of this study.

          8. Mental or medical instability makes patients unable or unwilling to sign informed
             consent.

          9. Patients after comprehensive assessment are considered by the investigators to be
             unsuitable for participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haitao Zhao</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese Academy of Medical Sciences &amp; Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianzhen Lin</last_name>
    <phone>18800158133</phone>
    <phone_ext>010-69156043</phone_ext>
    <email>zhaoht@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences &amp; Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhen Lin</last_name>
      <phone>18800158133</phone>
      <phone_ext>010-69156043</phone_ext>
      <email>zhaoht@pumch.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </results_reference>
  <results_reference>
    <citation>Moriguchi M, Umemura A, Itoh Y. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol. 2016 Aug;9(4):184-90. doi: 10.1007/s12328-016-0670-7. Epub 2016 Jul 11. Review.</citation>
    <PMID>27401471</PMID>
  </results_reference>
  <results_reference>
    <citation>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.</citation>
    <PMID>18650514</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.</citation>
    <PMID>19095497</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010 Oct 20;28(30):4581-6. doi: 10.1200/JCO.2010.29.3605. Epub 2010 Sep 20.</citation>
    <PMID>20855823</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodriguez R, Miller KM. Unravelling the genomic targets of small molecules using high-throughput sequencing. Nat Rev Genet. 2014 Dec;15(12):783-96. doi: 10.1038/nrg3796. Epub 2014 Oct 14. Review.</citation>
    <PMID>25311424</PMID>
  </results_reference>
  <results_reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </results_reference>
  <results_reference>
    <citation>Hofstatter E, Mehra K, Yushak M, Pusztai L. Tumor profiling and the incidentalome: patient decisions and risks. Future Oncol. 2015;11(24):3299-305. doi: 10.2217/fon.15.260. Epub 2015 Nov 12. Review.</citation>
    <PMID>26562094</PMID>
  </results_reference>
  <results_reference>
    <citation>Endrullat C, Glökler J, Franke P, Frohme M. Standardization and quality management in next-generation sequencing. Appl Transl Genom. 2016 Jul 1;10:2-9. doi: 10.1016/j.atg.2016.06.001. eCollection 2016 Sep. Review.</citation>
    <PMID>27668169</PMID>
  </results_reference>
  <results_reference>
    <citation>Gadgeel SM. Personalized Therapy of Non-small Cell Lung Cancer (NSCLC). Adv Exp Med Biol. 2016;890:203-22. doi: 10.1007/978-3-319-24932-2_11. Review.</citation>
    <PMID>26703806</PMID>
  </results_reference>
  <results_reference>
    <citation>Millner LM, Strotman LN. The Future of Precision Medicine in Oncology. Clin Lab Med. 2016 Sep;36(3):557-73. doi: 10.1016/j.cll.2016.05.003. Review.</citation>
    <PMID>27514468</PMID>
  </results_reference>
  <results_reference>
    <citation>Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res. 2015 Aug 15;21(16):3631-9. doi: 10.1158/1078-0432.CCR-14-2683. Epub 2015 Jan 7.</citation>
    <PMID>25567908</PMID>
  </results_reference>
  <results_reference>
    <citation>Li S, Mao M. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Lett. 2013 Nov 1;340(2):247-53. doi: 10.1016/j.canlet.2012.09.027. Epub 2012 Oct 12. Review.</citation>
    <PMID>23063663</PMID>
  </results_reference>
  <results_reference>
    <citation>Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016 Nov;65(5):1031-1042. doi: 10.1016/j.jhep.2016.05.035. Epub 2016 Jun 2. Review.</citation>
    <PMID>27262756</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 25, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

